cyrilzakka/clinical-trials huggingface dataset:
Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome

Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).

The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy. However, evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients. Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent.

In particular, the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk, such as preserved left ventricular systolic function or single-vessel disease. Therefore, we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI.

Eligibility Criteria:
Inclusion Criteria:

1. consecutive patients 18 years of age or older;
2. patients diagnosed as ACS(including STEMI、NSTEMI and UA) by doctor at discharge;
3. patients undergoing primary PCI.

Exclusion Criteria:

missing beta-blocker information.
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign

This program will provide patients with type 1 and high risk type 2 diabetes the safest hospitalization by using wireless continuous glucose monitoring devices (CGM) to track their glucose parameters in real-time similar to other continuously monitored vital signs. The CGM will inform a team of health professionals who will monitor the patients' progress, communicate recommendations, and be available for discussion when recommended targets are not achieved. Health teams will utilize sensor results in addition to existing electronic medical records data to evaluate progress and manage care.

All patients with type 1 or type 2 diabetes who meet study criteria will be invited to participate in the study. All patients included in the study will be followed by an advanced practice diabetes nurse for glucose management during their hospitalization. All patients included in the study will receive a CGM. Patients with type 2 diabetes will be randomized to control (blinded CGM glucose values to APN, care team and researchers) or intervention (CGM blood glucose values will be used to aid with glucose management during the hospitalization). In addition, a research only supplemental order set will be implemented for all study participants. The order set focuses on any glucose point of care test that is between 70-79 mg/dL or ≥ 250 at bedtime or before the 4 am usual care blood glucose check. The goal is to prevent hypoglycemia and hyperglycemia for all study patients. The advanced practice diabetes nurse will work with the physician in charge of the patient's care as well as the patient's care team.

Eligibility Criteria:
Inclusion Criteria:

* Expected length of hospital stay of at least 48 hours
* One of the following:

  1. Diagnosed with diabetes type 1 OR
  2. Diagnosed with diabetes type 2, with an HbA1c \> 8% or 3 point-of-care blood glucose (POC) \> 200, and requiring insulin during this hospitalization.
* Literate in English or Spanish

Exclusion Criteria (not all listed):

* Pregnant or post-partum
* Patient admitted to OB unit
* Patient in ICU or with insulin drip
* Known allergy to adhesives
* Anticipated CT/MRI/diathermy procedure within 48 hours from admission (patients with a planned operation within 48 hours from admission may be included in the study post operation).
To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy

This is a large-scale, multi-center, observational study. It is planned to establish a large database of 10,000 patients with type 2 diabetes mellitus to investigate the prevalence, awareness and screening rates of diabetes kidney disease (DKD), and provide real-world data on the efficacy and safety of sodium glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM).

Among the various complications of diabetes mellitus, DKD is considered as a major threat and is one of the manifestations of diabetic microangiopathy. it is one of the main causes of death for patients with T2DM.

Albuminuria is the earliest manifestation of DKD, which is mostly asymptomatic at the early stage, if the albuminuria is poorly controlled, it may develop into clinical DKD. Therefore, it is very important to improve the patients' awareness of DKD, regularly screen early kidney diseases and use drugs rationally.

In order to promote the standardization of diagnosis and treatment of patients with DKD, improve the knowledge and screening rate of patients with DKD, help the formation of health literacy, healthy behavior and lifestyle, the investigators planned the study.

STUDY OBJECTIVES:

1. To understand the epidemiological disease burden of DKD in China, and to investigate the prevalence rate, awareness rate and screening rate of DKD;
2. To understand the treatment status of patients with DKD in China;
3. To provide real-world data on the efficacy and safety of SGLT2i in the treatment of DKD in China;

Eligibility Criteria:
Inclusion Criteria:

* It is known that patients with T2DM has a history of more than 12 months (the WHO1999 Standard) and is treated with at least one anti-diabetic agent.
* Gender and age: men and women who are at least 18 years old with informed consent.
* Patients are willing and able to provide written informed consent before participating in this study.

Exclusion Criteria:

* Type 1 diabetes mellitus (DM)
* Patients with severe ketosis, diabetic coma, severe infection or severe trauma
* Perioperative patients
* Patients with severe renal impairment and advanced nephropathy (eGFR \< 45 ml/min/1.73m2)
* Renal transplant patients
* Patients are participating in or have participated in any other clinical trials in the past 3 months
* Any disease with a life expectancy of less than 2 years according to the clinical judgment of the investigator
* Pregnant or lactating women
* Patients judged by the investigator to be unsuitable for participating in the study.
Refractory Chronic Cluster Headache: Exploring the Potential of Repetitive Transcranial Magnetic Stimulation

The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are:

Does Transcranial Magnetic Stimulation lower the number of attacks per week in patients with refractory cluster headache ?

Researchers will compare transcranial magnetic stimlation to a sham stimulation (a look-alike stimulation) to see if it works to prevent attacks of cluster headache.

Participants will:

Recieve stimulation for 10 minutes for 10 consecutive working days in 2 periods of time, separated by a 1 month washout period.

Visit the clinic for each treatment day. Keep a diary of their symptoms and the number of times they use a rescue medication


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Diagnosed with Chronic Cluster Headache (CCH) based on the International Classification of Headache Disorders 3rd Edition
* Diagnosed with refractory CCH based on the European Headache Federation criteria of 2014.

Exclusion Criteria:

* History of epilepsy.
* Concomitant diagnosis of any other headache (if the patient was unable to differentiate between them).
* Carriers of any electronic device, or any additional contraindication for Transcranial Magnetic Stimulation, such as pregnancy.
IVF\ICSI Outcome in Women With Polycystic Ovary Syndrome

Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .

Sub-fertile women with PCOS will usually benefit from conventional treatments, such as lifestyle changes, ovulation induction, or laparoscopic ovarian drilling, but some will ultimately need assisted reproductive techniques, either if they will need or if they wish, such as controlled ovarian hyperstimulation and IVF.

In these cases, controlled ovarian hyperstimulation is closely related to high drug costs, need for daily injections and frequent monitoring, whereas it sometimes results in an increased rate of cycle cancellations and potential life threatening complications due to ovarian hyperstimulation syndrome and in the retrieval of immature oocytes, leading to poor fertilization and lower cleavage, pregnancy, and live birth rates compared to the conventional IVF cycles ,although this has not been confirmed by other studies .

In addition, ovulation induction is associated with a high risk of multiple pregnancies due to multiple follicular development, so that it has to be individualized and closely monitored.

In-vitro fertilization (IVF) is a common therapeutic modality used in infertile women. IVF has different success rates in different subgroups of patients.

It is necessary to alter the common standard protocols to overcome the potential obstacles in some populations of patients and achieve the best results . Obesity with PCOS status of patient may decrease the fertilization rate and clinical pregnancy chance after IVF (probably by decreasing the oocyte count and increasing the gonadotropin resistance); however, the results of different studies are conflicting

Eligibility Criteria:
Inclusion Criteria:

* Oligo-ovulation or anovulation.
* Clinical and/or biochemical hyper androgenesim.
* Polycystic ovaries.

Exclusion Criteria:

1. Androgen-secreting tumors (ovarian or adrenal).
2. Adult-onset congenital adrenal hyperplasia.
3. Thyroid diseases.
4. Cushing's syndrome.
5. Diabetes Mellitus.
6. recurrent ICSI failure
7. endocrine, hematologic and autoimmune disorders
8. Non chromosomal and genetic abnormalities
9. Major uterine anomalies, bad surgical history, sever endometriosis, , hydrosalpinx, uterine fibroids
10. Azospermia
Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

To compare the effectiveness of vaginal dinoprostone with placebo in minimising the pain experienced by postmenopausal patients during diagnostic ofﬁce hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body.Cervical ripening is made possible by the use of medication through different routes.The most commonly used agent is misoprostol,a synthetic prostaglandin E1 (PGE1) analogue that is frequently administered in off-label use in obstetrics and gynaecology for medical abortion, labor induction, endometrial biopsy, dilatation and curettage, intrauterine device insertion, myomectomy, postpartum haemorrhage, and cervical ripening.In contrast, dinoprostone, a natural PGE2, is mostly used in obstetrics for cervical ripening and the stimulation of uterine contractions to induce labor.

Eligibility Criteria:
Inclusion Criteria:

* Menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding or abnormal ultrasound ﬁndings)

Exclusion Criteria:

* • Nulliparous patients

  * patients with cervical pathology
  * retroverted uterus (detected by transvaginal ultrasound)
  * previous cervical surgery
  * patients with severe vaginal bleeding
  * allergy or contraindications to dinoprostone therapy (asthma, liver, kidney, or heart disease).
Telerehabilitation Upper Extremity for Neurological Disorders

The aims of the present study were to:

* Investigate the feasibility of using a therapeutic gaming system (REHAB@HOME), based on Kinect, to augment upper extremity neurorehabilitation services.
* Provide preliminary evidence of clinical efficacy of the approach in increasing arm activity and health related quality of life of persons post stroke or with MS.

Main results suggest that the serious games approach was positively received in terms of user experience and motivation to use, with the participants showing also improvements in functional abilities of the treated arm.

The objective of this pilot study was to assess the feasibility of using a therapeutic gaming system (REHAB@HOME), based on Kinect, to augment upper extremity neurorehabilitation services. A secondary objective was to provide preliminary evidence of clinical efficacy of the approach in increasing arm activity and health related quality of life of persons post stroke or with multiple sclerosis (MS).

A pilot single-blind randomized controlled trial was carried out in an inpatient and ambulatory care at a rehabilitation center. Twenty persons with multiple sclerosis (n=16) or chronic poststroke (n=4) receiving rehabilitation at the center, able to flex shoulder and elbow at least 45 degrees, participated in the study.

An intervention group received Serious Games-based upper extremity therapy for a total of 12 sessions (4-5 sessions, lasting 40 minutes, per week) and the control played the same amount of time with commercial exergames of the Wii. Both groups received their usual rehabilitation services as well as game playing.

Eligibility Criteria:
Inclusion Criteria:

* Persons Post stroke or with MS with resultant upper extremity motor deficits.
* Range of motion of shoulder and elbow equal or higher than 45 degrees.
* Able to comprehend and follow directions.

Exclusion Criteria:

* Wearing pace maker
* Comorbidities affecting arm use
* Not able to comprehend and follow directions
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of MS
* RMS and PPMS participants diagnosed according to the McDonald criteria of 2017
* First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab

Exclusion Criteria:

* Participation in interventional studies investigating DMTs for MS
* Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
* Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
* Severe psychiatric disability
* Pregnant and/or breastfeeding women
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.


Eligibility Criteria:
Key Inclusion Criteria:

* Primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of ASD
* Aberrant Behavior checklist - Irritability (ABC-I) subscale score of ≥ 18
* Clinical Global Impressions - Severity (CGI-S) scale score pertaining to irritability ≥ 4
* Mental age of ≥ 2 years as determined by Investigator based upon school participation, social history or medical records
* Ability for parent/caregiver to follow all protocol procedures
* Able to swallow tablets
* Able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period

Key Exclusion Criteria:

* Primary diagnosis of bipolar I disorder, including any DSM-5 current diagnosis of bipolar II disorder, schizophrenia, schizoaffective disorder, major depressive episode, and post-traumatic stress disorder (PTSD). Attention-deficit/hyperactivity disorder (ADHD) maybe exclusionary if it is the primary disorder, or is not stable or adequately treated.
* current or historical diagnosis of Fragile-X Syndrome or Rett's Disorder
* history of neuroleptic malignant syndrome
* a significant risk of committing violent acts, serious self-harm, or suicide
* epilepsy, a history of seizures, or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions
* current hypothyroidism or hyperthyroidism
* uncontrolled Type I or Type II diabetes
* uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
* Weight \< 15 kg
* Previous exposure to brexpiprazole
* Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study
Imaging Inflammation in Autoimmune Diabetes

The purpose of this study is to determine whether magnetic resonance imaging (MRI) with ferumoxtran-10 can be used to detect changes in the pancreas associated with autoimmune diabetes.

Approximately one million individuals are afflicted with autoimmune Type 1 diabetes mellitus (T1DM) in the United States. This disease results from the autoimmune destruction of the insulin-producing beta-cells of the islets of Langerhans of the pancreas. Initially, diabetes is usually clinically occult with localized pancreatic inflammation characterized by a lymphocytic infiltration of the pancreatic islets, termed insulitis, which leads to beta-cell specific destruction of the islets. This is often followed by the clinically overt phase that ensues when the bulk of beta cells have been destroyed and the pancreas is no longer able to produce sufficient insulin to maintain glycemic control. The purpose of this study is to assess the ability of magnetic resonance imaging with ferumoxtran-10, a functional molecular imaging agent consisting of iron oxide nanoparticles, to detect changes in the pancreas associated with the insulitis of T1DM.

Eligibility Criteria:
Inclusion Criteria:

* Recent onset type 1 diabetes as defined by clinical diagnosis within the last 6 months and age less than 30 or at least one islet autoantibody marker (GAD, IAA, or IA-2).

or

* High risk of pre-type 1 diabetes as defined by first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).

or

* Individuals with established type 1 diabetes of greater than 6 months duration who were under age 30 or at least one islet autoantibody marker positive (GAD, IAA, or IA-2) at time of diagnosis or who currently are GAD or IA-2 autoantibody marker positive.

or

* Normal control as defined by no family history of type 1 diabetes and normal tolerance test (tolerance testing to be performed as part of protocol).

Exclusion Criteria:

* Individuals under 18 years of age
* Individuals unable or unwilling to give informed consent/HIPAA authorization
* Individuals who are clinically unstable
* Individuals with any contraindications to MRI examination, for example, individuals with pacemakers
* Pregnant or lactating women
* Individuals with allergies to iron or dextran
* Individuals with a history of cirrhosis
Univu-guided Vein of Marshall Ethanol Infusion (Marshall-Merge)

The study is a prospective, randomized, single-blind clinical trial aiming to compare two method in guidance of Vein of Marshall ethanol infusion (VOMEI), i.e., the conventional fluoroscopy-guided VOMEI and UNIVU-guided VOMEI.

A total of 100 participants with persistent or longstanding persistent AF who undergo radiofrequency catheter ablation will be randomized assigned to two groups at 1:1 ratio to receive Vein of Marshall ethanol infusion (VOMEI).

Group 1: VOMEI guided by fluroscopy alone Group 2: VOMEI guided by fluoroscopy and CARTO UNIVU The intraprocedural major endpoints are the change in low-voltage area led by VOMEI (efficacy endpoint) and procedural complications (safety endpoint). The longterm major endpoint is the recurrence of atrial tachyarrhythmia between 3 and 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 85 years
* Sympathetic atrial fibrillation without previous ablation
* Persistent or long-standing persistent AF
* Patients' willing to undergo catheter ablation and VOMEI

Exclusion Criteria:

* Left atrial or left atrial appendage thrombus
* LVEF \<30%
* Cardiac surgery within 90 days
* Myocardial infarction within 90 days
* PCI or PTCA within 90 days
* Thromboembolic events within 90 days, including stroke, pulmonary embolism, systemic embolism
* Atrial myxoma
* Congenital heart disease
* Pregnant or pregnant plan
* Acute or severe infection
* Creatine\> 221 μmol/L, or GFR \<30 ml/min/1.73 m.
* Unstable angina
* Blood-clotting or bleeding disorder
* Contraindication to anticoagulation
* Life expectancy less than 1 year
* Uncontrolled heart failure
* Uncontrolled malignant tumor
* Malformation of femoral vascular access
* Without consent
Non-surgical Intervention for Carpal Tunnel Syndrome

This randomized controlled trial graduate student research study will explore the effect of non-surgical intervention of the dorsal application of Kinesio Tape for carpal tunnel syndrome, and forearm wrist hand pain.

This randomized controlled trial graduate student research study will explore the effect of non-surgical intervention of the dorsal application of Kinesio Tape for carpal tunnel syndrome, and forearm wrist hand pain. Little evidence exists for an effective non-surgical intervention. Semi-structured interviews will be conducted to explore changes in occupational performance and compliance in order to understand if Kinesio Tape contributed to results and if so, how the participants perceived the interventions.

Eligibility Criteria:
Inclusion Criteria:

* Adults \> 18 years of age
* Fluent in English
* Report signs and symptoms of carpal tunnel syndrome
* Pain, numbness, and tingling of the forearm, wrist, or hand, which worsen at night
* Demonstrate positive Phalen's Test or Tinel's Test of the affected extremity

Exclusion Criteria:

* Currently receiving treatment for carpal tunnel syndrome
* History of surgical carpal tunnel release
* Pregnant
* Diabetes not controlled by medication
* Radiculopathy ie: cervical radiculopathy, diabetic radiculopathy
* Thoracic outlet syndrome
* Allergy to adhesives or compromised skin integrity
* Past history of traumatic event, surgery, or congenital impairment of the forearm, wrist, or hand